- Details
- Description
-
Packaging Size7c&14c
-
Strength25mg&100mg
-
CompositonEnsartinib Hydrochloride
-
TreatmentALK-positive locally advanced or metastatic non-small cell lung cancer
-
FormCapsule
-
BrandEnsacove（贝美纳）
-
Quantity Unit25mg*7c/Box&100*14c/Box
-
ManufacturerBetta Pharma. china
About Ensartinib
Ensartinib is a novel, aminopyridazine-based small molecule that potently inhibits ALK. Ensartinib is 10-fold more potent than crizotinib at inhibiting the growth of ALK-positive lung cancer cell lines.Additionally, ensartinib potently inhibited ALK fusions engineered to have point mutations, L1196M and C1156Y, that are associated with crizotinib resistance. Ensartinib also demonstrated potent antitumor activity in H3122 lung cancer xenografts that harbored the EML4-ALK E13;A20 fusion, with favorable pharmacokinetic (PK) and safety profiles.
- Ensartinib sold under the brand name Ensacove® in USA.
- Ensartinib sold under the brand name 贝美纳® in china.
《FDA approves ensartinib for ALK-positive locally advanced or metastatic non-small cell lung cancer》
Dosage and administration
The recommended dose is 225 mg once daily, taken orally at the same time each day, on an empty stomach or with food.
If a dose of Ensartinib is missed and the interval between doses is more than 12 hours, the patient should take the missed dose.
If vomiting occurs during treatment, the patient should not take additional doses, but should continue to take the next scheduled dose.
